Hope for stargardt patients: phase 3 drug trial aims to halt vision decline
Disease control
Recruiting now
This study tests an investigational drug called gildeuretinol acetate (ALK 001) in 230 people aged 8 to 45 with Stargardt disease, an inherited condition that causes progressive vision loss. The goal is to see if the drug can slow the growth of damage in the retina and help prese…
Phase: PHASE3 • Sponsor: Alkeus Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 11:33 UTC